HTDS Hard To Treat Diseases Inc (CE)

Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary has had two vaccines for contagious diseases approved by Pakistan's Ministry of Health to be sold in the country.

It has taken several years of continuous efforts by Mellow Hope to have Hepatitis A Live Attenuated Vaccine (MEVAC-A) and Influenza Virus Vaccine, Inactivated (Split) (MEVAC-FLU) approved for use in Pakistan. The company is setting prices for the vaccines in anticipation of receiving registration certificates that will allow it to start taking orders.

Mellow Hope believes that the two vaccines will be launched successfully and become widely accepted by those who need them among Pakistan's 190 million residents. Improved performance in the world's sixth most populated country, where Hepatitis is a highly infectious and problematic disease, should increase profits for HTDS and add value for shareholders.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts: For medical and scientific dialogue inquiry only, please contact: medicalinfo@htdsmedical.com